Integrins as therapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 3, 2000, Pages 397-411

  Rose, David M ^a   Pozzi, Ambra ^a   Zent, Roy ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti integrin therapy; antibody; cancer; cyclic peptides; inflammation; integrins; leukocytes; matrix metalloproteinase; multiple sclerosis; platelets; transplant rejection; vascular disease

Indexed keywords

EID: 0000755542     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.3.397     Document Type: Review

References (125)

1. HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11-25. Review of integrin structure and function.
2. SCHWARTZ MA, SCHALLER MD, GINSBERG MH: Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell. Dev. Biol. (1995) 11:549-599. (Pubitemid 26019614)
3. GARDNER HA: Integrin signaling in fibrosis and scleroderma. Curr. Rheum. Reports. (1999) 1:28-33.
4. KATO A: The biological and clinical spectrum of Glanzmann's thrombasthenia: implications of integrin alpha IIb beta 3 for its pathogenesis. Crit. Rev. Oncol. Hematol. (1997) 26:1-23.
5. HODIVALA-DILKE KM, MCHUGH KP, TSKIRIS DA et al.: Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. (1999) 103:229-238. (Pubitemid 29053141)
6. HYNES RO, HODIVALA-DILKE KM: Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia. Thromb. Haemost. (1999) 82:481-485.
7. ANDERSON DC, SPRINGER TA: Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1 and p150,95 glycoproteins. Ann. Rev. Med. (1987) 38:175-194.
8. SCHARFFETTER-KOCHANEK K, LU H, NORMAN K et al.: Spontaneous skin ulceration and defective T cell function in CD18 null mice. J. Exp. Med. (1998) 188:119-131. (Pubitemid 28328611)
9. RUOSLAHTI E: RGD and other recognition sequences for integrins. Ann. Rev. Cell. Dev. Biol. (1996) 12:697-715. (Pubitemid 26422728)
10. HUGHES PE, PFAFF M: Integrin affinity modulation. Trends Cell. Biol. (1998) 8:359-364. (Pubitemid 28398427)
11. HAINES ST, BUSSEY HI: Thrombosis and the pharmacology of antithrombotic agents. Ann. Pharmacother. (1995) 29:892-905.
12. DU X, GINSBERG MH: Integrin alpha IIb beta 3 and platelet function. Thromb. Haemost. (1997) 78:96-100. (Pubitemid 27289223)
13. GINSBERG MH, DU X, O'TOOLE TE, LOFTUS JC: Platelet integrins. Thromb. Haemost. (1995) 74:352-359.
14. SAELMAN EU, KEHREL B, HESE KM et al.: Platelet adhesion to collagen and endothelial cell matrix under flow conditions is not dependent on platelet glycoprotein IV. Blood (1994) 83:3240-3244. (Pubitemid 24158469)
15. NIEUWENHUIS HK, AKKERMAN JW, HOUDIJK WT, SIXMA JJ: Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1985) 318:470-472. (Pubitemid 16195848)
16. DEPRAETERE H, WILLE C, GANSEMANS Y et al.: The integrin alpha 2 beta 1 (GPIa/IIa)-I-domain inhibits platelet-collagen interaction. Thromb. Haemost. (1997) 77:981-985. (Pubitemid 27239126)
17. IVASKA J, KAPYLA J, PENTIKAINEN O et al.: A peptide inhibiting the collagen binding function of integrin alpha2I domain. J. Biol. Chem. (1999) 274:3513-3521. (Pubitemid 29077192)
18. PENTIKAINEN O, HOFFERN AM, IVASKA J et al.: 'RKKH' peptides from the snake venom metalloproteinase of Bothrops jararaca bind near the metal ion-dependent adhesion site of the human integrin alpha(2) I-domain. J. Biol. Chem. (1999) 274:31493-31505.
19. EMSLEY J, KING SL, BERGELSON JM, LIDDINGTON RC: Crystal structure of the I domain from integrin alpha2beta1. J. Biol. Chem. (1997) 272:28512-28517. (Pubitemid 27517800)
20. EMSLEY J, KNIGHT CG, FARNDALE RW, BARNES MJ, LIDDINGTON RC: Structural basis of collagen recognition by integrin alpha2beta1. Cell (2000) 101:47-56.
21. SHATTIL SJ, KASHIWAGI H, PAMPORI N: Integrin signaling: the platelet paradigm. Blood (1998) 91:2645-2657. (Pubitemid 28227512)
22. TOPOL EJ, BYZOVA TV, PLOW EF: Platelet GPIIb-IIIa blockers [see comments]. Lancet (1999) 353:227-231. (Pubitemid 29088046)
23. FAULDS D, SORKIN EM: Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs (1994) 48:583-598.
24. PHILLIPS DR, SCARBOROUGH RM: Clinical pharmacology of eptifibatide. Am. J. Cardiol. (1997) 80:11B-20B. (Pubitemid 27369147)
25. FARRELL DH, THIAGARAJAN P, CHUNG DW, DAVIE EW: Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc. Natl. Acad. Sci. USA (1992) 89:10729-10732.
26. SCHAFER AI: Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Tex Heart Inst. J. (1997) 24:90-96. (Pubitemid 27273124)
27. EGBERTSON MS, CHANG CT, DUGGAN ME et al.: Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. (1994) 37:2537-2551. (Pubitemid 24276781)
28. SALAME M, VERHEYE S, MORE R, KING SB, 3RD, CHRONOS N: GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction. Int. J. Cardiol. (1999) 69:231-236. (Pubitemid 29254098)
29. KONG DF, CALIFF RM: Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. Drugs (1999) 58:609-620. (Pubitemid 29520508)
30. KONG DF, CALIFF RM, MILLER DP et al.: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1998) 98:2829-2835. (Pubitemid 29003963)
31. WHITE HD: Newer antiplatelet agents in acute coronary syndromes. Am. Heart J. (1999) 138:S570-576.
32. VORCHHEIMER DA, FUSTER V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety [editorial; comment]. Circulation (1998) 97:312-314. (Pubitemid 28074329)
33. SHIMIZU Y, ROSE DM, GINSBERG MH: Integrin in the immuno system. Adv. Immunol. (1999) 72:325-380.
34. STEWART M, THIEL M, HOGG N: Leukocyte integrins. Curr. Opin. Cell. Biol. (1995) 7:690-696.
35. PICARELLA D, HURLBUT P, ROTTMAN J, SHI X, BUTCHER E, RINGLER DJ: Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. (1997) 158:2099-2106. (Pubitemid 127469991)
36. HESTERBERG PE, WINSOR-HINSE D, BRISKIN MJ et al.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology (1996) 111:1373-1380. (Pubitemid 26362264)
37. HIRSCH E, IGLESIAS A, POTOCNIK AJ, HARTMANN U, FASSLER R: Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Nature (1996) 380:171-175. (Pubitemid 26085885)
38. ARROYO AG, YANG JT, RAYBURN H, HYNES RO: Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell (1996) 85:997-1008. (Pubitemid 26231167)
39. SCHMITS R, KUNDIG TM, BAKER DM et al.: LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med. (1996) 183:1415-1426. (Pubitemid 26134285)
40. WAGNER N, LOHLER J, KUNKEL EJ et al.: Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature (1996) 382:366-370. (Pubitemid 26260466)
41. SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301-314. (Pubitemid 24046692)
42. ISOBE M, YAGITA H, OKUMURA K, IHARA A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science (1992) 255:1125-1127.
43. O'TOOLE TE, KATAGIRI Y, FAULL RJ et al.: Integrin cytoplasmic domains mediate inside-out signal transduction. J. Cell. Biol. (1994) 124:1047-1059. (Pubitemid 24109406)
44. ZHANG Z, VUORI K, WANG H, REED JC, RUOSLAHTI E: Integrin activation by R-ras. Cell (1996) 85:61-69. (Pubitemid 26116807)
45. HUGES PE, RENSHAW MW, PFAFF M et al.: Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell (1997) 88:521-530. (Pubitemid 27154417)
46. WU C, KEIVENS VM, O'TOOLE TE, MCDONALD JA, GINSBERG MH: Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell (1995) 83:715-724.
47. LIU S, THOMAS SM, WOODSIDE DG et al.: Binding of paxillin to alpha4 integrins modifies integrindependent biological responses. Nature (1999) 402:676-681. (Pubitemid 129516339)
48. KLING D, FINGERLE J, HARLAN JM, LOBB RR, LANG F: Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18-and VLA-4-dependent mechanisms and stimulate smooth muscle migration. Circ. Res. (1995) 77:1121-1128.
49. WINN RR, HARLAN JH: Anti-adhesion therapy. Adv. Pharmacol. (1997) 39:99-142.
50. MULLIGAN MS, VARANI J, WARREN JS et al.: Roles of beta 2 integrins of rat neutrophils in complement-and oxygen radical-mediated acute inflammatory injury. J. Immunol. (1992) 148:1847-1857.
51. KISHIMOTO TK, ROTHLEIN R: Integrins, ICAMs and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv. Pharmacol. (1994) 25:117-169.
52. MULLIGAN MS, VAPORCIYAN AA, WARNER RL et al.: Compartmentalized roles for leukocytic adhesion molecules in lung inflammatory injury. J. Immunol. (1995) 154:1350-1363.
53. SHARAR SR, WINN RK, MURRY CE, HARLAN JM, RICE CL: A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery (1991) 110:213-219; discussion 219-220.
54. MILESKI WJ, WINN RK, HARLAN JM, RICE CL: Transient inhibition of neutrophil adherence with the anti-CD18 monoclonal antibody 60.3 does not increase mortality rates in abdominal sepsis. Surgery (1991) 109:497-501.
55. HOURMANT M, LE MAUFF B, LEMEUR Y et al.: Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study. Transplantation (1994) 58:377-380. (Pubitemid 24252296)
56. LE MAUFF B, LE MEUR Y, HOURMANT M et al.: A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients. Kidney Int. Suppl. (1996) 53:S44-50. (Pubitemid 26024310)
57. ABRAHAM WM, SIELCZAK MW, AHMED A et al.: Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J. Clin. Invest. (1994) 93:776-787.
58. YEDNOCK TA, CANNON C, FRITZ LC et al.: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 356:63-66.
59. BARON JL, REICH EP, VISINTIN I, JANEWAY CA, JR.: The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J. Clin. Invest. (1994) 93:1700-1708. (Pubitemid 24116411)
60. CHISHOLM PL, WILLIAMS CA, LOBB RR: Monoclonal antibodies to the integrin alpha-4 subunit inhibit the murine contact hypersensitivity response. Eur. J. Immunol. (1993) 23:682-688. (Pubitemid 23095104)
61. SHEREMATA WA, VOLLMER TL, STONE LA, WILLMERHULME AJ, KOLLER M: A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology (1999) 52:1072-1074. (Pubitemid 29161624)
62. TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group [see comments]. Neurology (1999) 53:466-472. (Pubitemid 29382036)
63. LIN KC, CASTRO AC: Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr. Opin. Chem. Biol. (1998) 2:453-457. (Pubitemid 128645697)
64. KOMORIYA A, GREEN LJ, MERVIC M et al.: The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced Type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem. (1991) 266:15075-15079. (Pubitemid 21907620)
65. WANG JH, PEPINSKY RB, STEHLE T et al.: The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): a cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1-alpha 4 integrin interaction. Proc. Natl. Acad. Sci. USA (1995) 92:5714-5718.
66. WAYNER EA, KOVACH NL: Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J. Cell Biol. (1992) 116:489-497.
67. KAMATA T, PUZON W, TAKADA Y: Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29). Biochem. J. (1995) 305:945-951.
68. IIDA J, SKUBITZ AP, FURCHT LT, WAYNER EA, MCCARTHY JB: Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J. Cell. Biol. (1992) 118:431-444.
69. MOLOSSI S, ELICES M, ARRHENIUS T et al.: Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J. Clin. Invest. (1995) 95:2601-2610.
70. ABRAHAM WM, AHMED A, SIELCZAK MW, NARITA M, ARRHENIUS T, ELICES MJ: Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am. J. Respir. Crit. Care Med. (1997) 156:696-703. (Pubitemid 27396403)
71. LIN K, ATEEQ HS, HSIUNG SH et al.: Selective, tightbinding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J. Med. Chem. (1999) 42:920-934. (Pubitemid 29136181)
72. CASANOVAS JM, SPRINGER TA, LIU JH, HARRSON SC, WANG JH: Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Nature (1997) 387:312-315. (Pubitemid 27220770)
73. MOYLE M, FOSTER DL, MCGRATH DE et al.: A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. J. Biol. Chem. (1994) 269:10008-10015. (Pubitemid 24196615)
74. GONZALEZ-AMARO R, DIAZ-GONZALES F, SANCHEZMADRID F: Adhesion molecules in inflammatory diseases. Drugs (1998) 56:977-988. (Pubitemid 29010217)
75. PILLINGER MH, CAPODICI C, ROSENHTHAL P et al.: Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc. Natl. Acad. Sci. USA (1998) 95:14540-14545. (Pubitemid 28549403)
76. FOLKMAN J, SHING Y: Angiogenesis. J. Biol. Chem. (1992) 267:10931-10934.
77. FIDLER IJ, ELLIS LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 79:185-188. (Pubitemid 24324908)
78. PAKU S, PAWELETZ N: First steps of tumor-related angiogenesis. Lab. Invest. (1991) 65:334-346.
79. RISAU W: Mechanisms of angiogenesis. Nature (1997) 386:671-674. (Pubitemid 27193480)
80. BECK LJ, D'AMORE PA: Vascular development: cellular and molecular regulation. FASEB J. (1997) 11:365-373. (Pubitemid 27193941)
81. MUSTONEN T, ALITAL K: Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell. Biol. (1995) 129:895-898.
82. FOLKMAN J, D'AMORE PA: Blood vessel formation: what is its molecular basis? Cell (1996) 87:1153-1155. (Pubitemid 27010098)
83. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79:315-328. (Pubitemid 24324921)
84. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277-285. (Pubitemid 28015876)
85. STREIT M, RICCARDI L, VELASCO P et al.: Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA (1999) 96:14888-14893. (Pubitemid 30019735)
86. BLEUEL K, POPP S, FUSENIG NE, STANBRIDGE EJ, BOUKAMP P: Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl. Acad. Sci. USA (1999) 96:2065-2070. (Pubitemid 29117868)
87. O'REILLY MS, PIRIE-SHEPHERD S, LANE WS, FOLKMAN J: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science (1999) 285:1926-1928.
88. BROOKS PC: Role of integrins in angiogenesis. Eur. J. Cancer. (1996) 32A:2423-2429.
89. HYNES RO, BADER BL, HODIVALA-DILKE K: Integrins in vascular development. Braz. J. Med. Biol. Res. (1999) 32:501-510. (Pubitemid 129540411)
90. STETLER-STEVENSON WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. (1999) 103:1237-1241. (Pubitemid 29218293)
91. LUSCINSKAS FW, LAWLER J: Integrins as dynamic regulators of vascular function. FASEB J. (1994) 8:929-938. (Pubitemid 24286856)
92. POLVERINI PJ: Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am. J. Pathol. (1996) 148:1023-1029.
93. VARNER JA, BROOKS PC, CHERESH DA: The integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes. Commun. (1995) 3:367-374.
94. BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 264:569-571.
95. HAUBNER R, WESTER HJ, REUNING U et al.: Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. (1999) 40:1061-1071. (Pubitemid 29269229)
96. BADER BL, RAYBURN H, CROWLEY D, HYNES RO: Extensive vasculogenesis, angiogenesis and organogenesis precede lethality in mice lacking all alpha v integrins. Cell (1998) 95:507-519. (Pubitemid 28533307)
97. DIAZ-GONZALES F, FORSYTH J, STEINER B, GINSBERG MH: Trans-dominant inhibition of integrin function. Mol. Biol. Cell. (1996) 7:1939-1951. (Pubitemid 26415001)
98. SENGER DR, CLAFFEY KP, BENES JE et al.: Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. USA (1997) 94:13612-13617.
99. POZZI A, MOBERG PE, MILES LA et al.: Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA (2000) 97:2202-2207. (Pubitemid 30134046)
100. LEAVESLEY DI, SCHWARTZ MA, ROSENFELD M, CHERESH DA: Integrin beta 1-and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell. Biol. (1993) 121:163-170. (Pubitemid 23097372)
101. DAVIS CM, DANEHOWER SC, LAURENZA A, MOLONY JL: Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J. Cell. Biochem. (1993) 51:206-218. (Pubitemid 23058578)
102. YANG JT, RAYBURN H, HYNES RO: Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development (1993) 119:1093-1105. (Pubitemid 23358579)
103. CLEZARDIN P: Recent insights into the role of integrins in cancer metastasis. Cell. Mol. Life Sci. (1998) 54:541-548. (Pubitemid 28325627)
104. FORGET MA, DESROSIERS RR, BELIVEAU R: Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can. J. Physiol. Pharmacol. (1999) 77:465-480. (Pubitemid 29500892)
105. RAVANTI L, HEINO J, LOPEZ-OTIN C, KAHIRI VM: Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. (1999) 274:2446-2455.
106. RIIKONEN T, WESTMARCK J, KOIVISTO L, BROBERG A, KAHARI VM, HEINO J: Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression. J. Biol. Chem. (1995) 270:13548-13552.
107. VO HP, LEE MK, CROWE DL: alpha2beta1 integrin signaling via the mitogen activated protein kinase pathway modulates retinoic acid-dependent tumor cell invasion and transcriptional downregulation of matrix metalloproteinase 9 activity. Int. J. Oncol. (1998) 13:1127-1134.
108. WERB Z, TREMBLE PM, BEHRENDTSEN O, CROWLEY E, DAMSKY CH: Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J. Cell. Biol. (1989) 109:877-889. (Pubitemid 19197045)
109. ESPARZA J, VILARDELL C, CALVO J et al.: Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood (1999) 94:2754-2766. (Pubitemid 29477304)
110. LARJAVA H, LYONS JG, SALO T et al.: Anti-integrin antibodies induce Type IV collagenase expression in keratinocytes. J. Cell. Physiol. (1993) 157:190-200. (Pubitemid 23300679)
111. CHINTALA SK, SAWAYA R, GOKASLAN ZL, RAO JS: Modulation of matrix metalloprotease-2 and invasion in human glioma cells by alpha 3 beta 1 integrin. Cancer Lett. (1996) 103:201-208. (Pubitemid 26147699)
112. LAUER JL, GENDRON CM, FIELDS GB: Effect of ligand conformation on melanoma cell alpha3beta1 integrin-mediated signal transduction events: implications for a collagen structural modulation mechanism of tumor cell invasion. Biochemistry (1998) 37:5279-5287. (Pubitemid 28176529)
113. LOCHTER A, NAVRE M, WERB Z, BISSELL MJ: alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol. Biol. Cell. (1999) 10:271-282. (Pubitemid 29156472)
114. POZZI A, WARY KK, GIANCOTTI FG, GARDNER HA: Integrin alpha1beta1 mediates a unique collagendependent proliferation pathway in vivo. J. Cell. Biol. (1998) 142:587-594. (Pubitemid 28361562)
115. GARDNER H, BROBERG A, POZZI A, LAATO M, HEINO J: Absence of integrin alpha1beta1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J. Cell. Sci. (1999) 112:263-272. (Pubitemid 29080649)
116. VAISANEN A, KALLIONEN M, TASKINEN PJ, TURPEENNIEMI-HUJANEN T: Prognostic value of MMP-2 immunoreactive protein (72 kD Type IV collagenase) in primary skin melanoma. J. Pathol. (1998) 186:51-58. (Pubitemid 28407488)
117. LEE KS, RHA SY, KIM SJ et al.: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin. Exp. Metastasis (1996) 14:512-519. (Pubitemid 27006983)
118. BROOKS PC, STROMBLAD S, SANDERS LC et al.: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85:683-693. (Pubitemid 26181048)
119. BROOKS PC, SILETTI S, VON SCHALSCHA TL, FRIEDLANDER M, CHERESCH DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 92:391-400. (Pubitemid 28093016)
120. ROTHENBERG ML, NELSON AR, HANDE KR: New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells (1999) 17:237-240.
121. BERNHARD EJ, GRUBER SB, MUSCHEL RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA (1994) 91:4293-4297. (Pubitemid 24143419)
122. BERNHARD EJ, HAGNER B, WONG C LUBENSKI I, MUSCHEL RJ: The effect of E1A transfection on MMP-9 expression and metastatic potential. Int. J. Cancer (1995) 60:718-724.
123. YAMAMOTO H, ITOH F, HINODA Y, IMAI K: Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int. J. Cancer (1995) 61:218-222.
124. MURPHY G, STANTON H, COWELL S et al.: Mechanisms for pro matrix metalloproteinase activation. APMIS (1999) 107:38-44. (Pubitemid 29133521)
125. GOMEZ DE, ALONSO DF, YOSHIJI H, THORGEIRSSON UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. (1997) 74:111-122. (Pubitemid 27455388)